Trial Condition(s):
Magnetic Resonance Imaging, Liver neoplasms
Study to evaluate the diagnostic efficacy of Gd-EOB-DTPA in the characterization of focal liver lesions
Bayer Identifier:
90391
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
235
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
A multi-center (US) open-label study of Gd-EOB-DTPA with a single intravenous injection (25 μmol/kg body weight) in patients with known or suspected focal liver lesions and the corresponding blinded reading to evaluate the diagnostic efficacy of Gd-EOB-DTPA in the characterization of focal liver lesions
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
